Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706
- Author
- HUSSEIN, M. A1 ; GUNDACKER, H2 ; HEAD, D. R3 ; ELIAS, L4 ; FOON, K. A5 ; BOLDT, D. H6 ; DOBIN, S. M7 ; DAKHIL, S. R8 ; BUDD, G. T1 ; APPELBAUM, F. R9
[1] Cleveland Clinic Foundation, Myeloma Program, Cleveland, OH, United States
[2] Department of Pathology, Southwest Oncology Group Statistical Center, Seattle, WA, United States
[3] Department of Internal Medicine, Division of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN, United States
[4] Department of Internal Medicine, Division of Hematology and Oncology, University of New Mexico, Albuquerque, NM, United States
[5] Department of Medicine, Division of Hematology, University of Cincinnati, Cincinnati, OH, United States
[6] Department of Pathology, University of Texas Health Science Center, San Antonio, TX, United States
[7] Scott & White Hospital, Temple, TX, United States
[8] Taussig, Cancer Center, Wichita Community Clinical Oncology Program, Wichita, KS, United States
[9] Puget Sound Oncology Consortium, Seattle, WA, United States - Source
Leukemia. 2005, Vol 19, Num 11, pp 1880-1886, 7 p ; ref : 26 ref
- CODEN
- LEUKED
- ISSN
- 0887-6924
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Nature Publishing, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Chronique Cyclophosphamide Essai clinique phase II Fludarabine Hématologie Leucémie lymphoïde Analogue nucléotide Agent alkylant Antimétabolite Fluor Composé organique Hémopathie maligne Lymphoprolifératif syndrome Moutarde à l'azote Oxazaphosphinane dérivé Purine nucléotide
- Keyword (en)
- Antineoplastic agent Chronic Cyclophosphamide Phase II trial Fludarabine Hematology Chronic lymphocytic leukemia Alkylating agent Antimetabolic Fluorine Organic compounds Malignant hemopathy Lymphoproliferative syndrome Nitrogen mustard Oxazaphosphinane derivatives Purine nucleotide
- Keyword (es)
- Anticanceroso Crónico Ciclofosfamida Ensayo clínico fase II Fludarabina Hematología Leucemia linfoidea Agente alquilante Antimetabólito Fluor Compuesto orgánico Hemopatía maligna Linfoproliferativo síndrome Mostaza al nitrógeno Oxazafosfinano derivado Purina nucleótido
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17205200
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.leu.2403940 
https://dx.doi.org/10.1038/sj.leu.2403940
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403940\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1880\";s:8:\"\u0000*\u0000epage\";s:4:\"1886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HUSSEIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"GUNDACKER, H\";i:1;s:10:\"HEAD, D. R\";i:2;s:8:\"ELIAS, L\";i:3;s:10:\"FOON, K. A\";i:4;s:11:\"BOLDT, D. H\";i:5;s:11:\"DOBIN, S. M\";i:6;s:12:\"DAKHIL, S. R\";i:7;s:10:\"BUDD, G. T\";i:8;s:15:\"APPELBAUM, F. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403940\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1880\";s:8:\"\u0000*\u0000epage\";s:4:\"1886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HUSSEIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"GUNDACKER, H\";i:1;s:10:\"HEAD, D. R\";i:2;s:8:\"ELIAS, L\";i:3;s:10:\"FOON, K. A\";i:4;s:11:\"BOLDT, D. H\";i:5;s:11:\"DOBIN, S. M\";i:6;s:12:\"DAKHIL, S. R\";i:7;s:10:\"BUDD, G. T\";i:8;s:15:\"APPELBAUM, F. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403940\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403940\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1880\";s:8:\"\u0000*\u0000epage\";s:4:\"1886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HUSSEIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"GUNDACKER, H\";i:1;s:10:\"HEAD, D. R\";i:2;s:8:\"ELIAS, L\";i:3;s:10:\"FOON, K. A\";i:4;s:11:\"BOLDT, D. H\";i:5;s:11:\"DOBIN, S. M\";i:6;s:12:\"DAKHIL, S. R\";i:7;s:10:\"BUDD, G. T\";i:8;s:15:\"APPELBAUM, F. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403940\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1880\";s:8:\"\u0000*\u0000epage\";s:4:\"1886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HUSSEIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"GUNDACKER, H\";i:1;s:10:\"HEAD, D. R\";i:2;s:8:\"ELIAS, L\";i:3;s:10:\"FOON, K. A\";i:4;s:11:\"BOLDT, D. H\";i:5;s:11:\"DOBIN, S. M\";i:6;s:12:\"DAKHIL, S. R\";i:7;s:10:\"BUDD, G. T\";i:8;s:15:\"APPELBAUM, F. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403940\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1880\";s:8:\"\u0000*\u0000epage\";s:4:\"1886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HUSSEIN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:12:\"GUNDACKER, H\";i:1;s:10:\"HEAD, D. R\";i:2;s:8:\"ELIAS, L\";i:3;s:10:\"FOON, K. A\";i:4;s:11:\"BOLDT, D. H\";i:5;s:11:\"DOBIN, S. M\";i:6;s:12:\"DAKHIL, S. R\";i:7;s:10:\"BUDD, G. T\";i:8;s:15:\"APPELBAUM, F. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:112:\"Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia : a phase II SWOG TRIAL 9706\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
